Management of Hepatitis C in Children - A New Paradigm

Ujjal Poddar1, D V Umesh Reddy2

  • 1Department of Pediatric Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh. Correspondence to: Dr Ujjal Poddar, Professor and Head, Department of Pediatric Gastroenterology, SGPGIMS, Raebareli Road, Lucknow 226 014, Uttar Pradesh. ujjalpoddar@hotmail.com.

Indian Pediatrics
|January 14, 2023
PubMed

Insights

Direct-acting antivirals (DAAs) have revolutionized hepatitis C (HCV) treatment in children, offering high efficacy and safety. Current DAA regimens simplify management for pediatric HCV infection, marking a significant advancement.

Area of Science:

  • Pediatric Hepatology
  • Virology
  • Pharmacotherapy

Background:

  • Hepatitis C virus (HCV) infection in children historically presented treatment challenges with interferon-based regimens.
  • Previous treatments for pediatric HCV infection showed limited efficacy (58% SVR) and significant side effects (52%).

Approach:

  • A literature search was conducted on PubMed, focusing on pediatric HCV (ages 0-18) treatment options.
  • The review analyzes the evolution of HCV management from older therapies to modern direct-acting antivirals (DAAs).

Key Points:

  • Direct-acting antivirals (DAAs) demonstrate high efficacy (92%-100% SVR12) and excellent safety profiles in children over three years old.
  • DAA regimens represent the current standard of care for pediatric hepatitis C infection.
  • Treatment simplification is a key outcome of DAA availability for pediatric HCV.

Conclusions:

  • DAA therapy has transformed pediatric HCV management, making treatment simpler and more effective.
  • Eliminating HCV in children requires continued DAA accessibility, public awareness, and improved screening strategies.
Abstract

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
116
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
210
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.4K